Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.
about
Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical TrialsAdditive effects of atorvastatin combined with sitagliptin on rats with myocardial infarction: a pilot studyThe nonglycemic actions of dipeptidyl peptidase-4 inhibitorsPleiotropic effects of the dipeptidylpeptidase-4 inhibitors on the cardiovascular systemEffect of dipeptidyl peptidase 4 inhibition on arterial blood pressure is context dependent.The favorable kinetics and balance of nebivolol-stimulated nitric oxide and peroxynitrite release in human endothelial cells.DPP-4 Inhibitor Reduces Central Blood Pressure in a Diabetic and Hypertensive Patient: A Case Report.Effects and mechanism of moderate aerobic exercise on impaired fasting glucose improvementEffect of Dipeptidyl Peptidase-4 Inhibitor on All-Cause Mortality and Coronary Revascularization in Diabetic Patients.Amlodipine increased endothelial nitric oxide and decreased nitroxidative stress disproportionately to blood pressure changes.Blood pressure control in type 2 diabetic patients.Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition.Dipeptidyl peptidase-4 inhibitors in cardioprotection: a promising therapeutic approach.Is there a role for the incretin system in blood pressure regulation?Potential impact of dipeptidyl peptidase-4 inhibitors on cardiovascular pathophysiology in type 2 diabetes mellitus.Vascular protection with dipeptidyl peptidase-IV inhibitors in diabetes: experimental and clinical therapeutics.Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes.DPP4 in cardiometabolic disease: recent insights from the laboratory and clinical trials of DPP4 inhibition.Postprandial Dysmetabolism and Oxidative Stress in Type 2 Diabetes: Pathogenetic Mechanisms and Therapeutic Strategies.Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS.Interpreting Cardiovascular Endpoints in Trials of Antihyperglycemic Drugs.Effect of dipeptidyl peptidase-4 inhibition on circadian blood pressure during the development of salt-dependent hypertension in rats.The contributions of dipeptidyl peptidase IV to inflammation in heart failure.Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes.New Antihyperglycemic Drugs and Heart Failure: Synopsis of Basic and Clinical Data.Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.A Possible Mechanism: Vildagliptin Prevents Aortic Dysfunction through Paraoxonase and Angiopoietin-Like 3.
P2860
Q28081569-134105AC-45F0-413B-B261-11B2B561E31EQ33904475-C5636937-4613-4E1D-92C7-B865212EDC55Q34029715-FEF02BD9-DF07-4C76-8949-C077371AE9F5Q34062829-E1FE42DD-BFF4-4DF9-BBE0-109E1E50CE0CQ34718326-2BA0AFD8-B302-468B-86CB-0E5F28953F5AQ35001265-AE1F4556-74A9-4109-A279-BBC810E64632Q35858226-2DAFBC1D-9468-4A99-AE11-C3A9AC0307E6Q36344151-021B81CF-8319-4A52-84A0-C10A03FA5EB7Q36448319-4AC02144-88DF-46B9-BC1D-8FA9503D4858Q37561135-F179230B-CEFF-4AE8-B869-3342278C7F41Q37566950-D12D4A98-505D-4B9E-A6D9-E8C02B0FFAA5Q37699068-B70B1D1B-3006-4B25-A489-FF41319BE28DQ38119146-F5B0E103-147F-447F-B034-9A1B3084FD0CQ38182499-EA4BDE0B-9610-4DF5-AF33-9BAF952C74F6Q38219481-61DAE01C-478D-48CD-9983-A259E2EBDCDEQ38371242-7660BFCA-385D-455E-AE80-0CB5085CA203Q38410742-F927529E-703E-4702-99CE-49715D1C4320Q38413395-65867233-E9F1-4D9E-875A-12A1EA95C2D9Q38460480-F96C35F2-ACB3-4A33-B684-7454B3FF1A6AQ38663559-23A476D2-984A-45BA-B8A6-25EC9D488165Q39136054-307702D8-8A2F-4C1F-A3C3-5FBF042D10F6Q39413684-0CA55362-DEC9-4A1F-A29F-03F35CA3BF90Q39751432-15228504-7A15-4D6F-B4C1-82A55D9850D6Q40534109-568D150F-757C-40D2-AE1A-BEAF6302E208Q47113843-9843652B-6F96-44EB-921E-E51C8F3CB801Q53145102-A94ADF70-1B73-4392-A4AC-AE2FF418BFCFQ55382850-C37B0DCB-09B7-4368-AB2E-208786F472B3
P2860
Dipeptidyl peptidase-4 inhibition with saxagliptin enhanced nitric oxide release and reduced blood pressure and sICAM-1 levels in hypertensive rats.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
Dipeptidyl peptidase-4 inhibit ...... 1 levels in hypertensive rats.
@en
Dipeptidyl peptidase-4 inhibit ...... 1 levels in hypertensive rats.
@nl
type
label
Dipeptidyl peptidase-4 inhibit ...... 1 levels in hypertensive rats.
@en
Dipeptidyl peptidase-4 inhibit ...... 1 levels in hypertensive rats.
@nl
prefLabel
Dipeptidyl peptidase-4 inhibit ...... 1 levels in hypertensive rats.
@en
Dipeptidyl peptidase-4 inhibit ...... 1 levels in hypertensive rats.
@nl
P2093
P1476
Dipeptidyl peptidase-4 inhibit ...... 1 levels in hypertensive rats.
@en
P2093
Aleksander Ciszewski
J Jose Corbalan
R Preston Mason
Robert F Jacob
Ruslan Kubant
Tadeusz Malinski
P304
P356
10.1097/FJC.0B013E31826BE204
P577
2012-11-01T00:00:00Z